Objective: This study evaluated the effect of indication for use (IFU), additional graft components, and percutaneous closure of endovascular aortic repair (PEVAR) on clinical outcomes and cost of endovascular aortic repair (EVAR).
During the past decade, endovascular aortic repair (EVAR) of abdominal aortic aneurysms (AAAs) has emerged as standard practice. Currently, >70% of elective AAA repairs are treated by EVAR in the United States.
1 Excellent technical success rates of 97% to 100% have been reported. 2, 3 A key tenet of this success is absence of type I or III endoleak at case completion because of associated rupture risk. 4 Intraoperative resolution of these leaks through secondary procedures has undoubtedly contributed to superior results, but failure of the index graft to achieve an adequate seal necessitating placement of additional aortic cuffs or limb extenders could theoretically increase the risk of endoleak redevelopment or other complications during follow-up. Studies reporting the effect of indication for use (IFU) on outcome have been inconsistent. Placement of grafts outside of IFU has been associated with increased perioperative mortality and graft-related complications 5 ; yet, others have reported successful outcome for EVAR performed in complex anatomy. 6, 7 Physicians have widely endorsed EVAR because of improved hospital outcomes. 8, 9 But EVAR is expensive, primarily because of high endograft cost, 10 which has resulted in negative operating margins for hospitals. 11 The clinical and financial effect from placement of adjunctive endograft components and its relationship to IFU are unknown. Similarly, percutaneous closure of EVAR (PEVAR) has been reported as clinically advantageous, 12 ,13 yet cost-to-benefit ratios have not been examined. Surgeons must be knowledgeable of cost and outcome dynamics to advocate for EVAR and themselves, particularly because many hospitals routinely incorporate fiscal and outcome measures in physician performance appraisals. This study evaluated the effect of IFU, additional graft components, and PEVAR on clinical outcomes and costs of EVAR.
METHODS
We retrospectively reviewed all elective EVARs for infrarenal AAAs at a university-affiliated hospital during a 1.5-year period. This review was a quality assurance project that stemmed from our previous study on the clinical feasibility and financial effect of same-day discharge for EVAR, 10 which was approved by the University's Health Science Institutional Review Board and for which informed consent was waived. The hospital data system (Eclipsys) was queried for the International Classification of Disease, 9th Revision Clinical Modification procedure code 39.71 (endovascular repair of abdominal aortic aneurysm) to identify the sample. Data collected from patient medical records included demographics, insurance, comorbidities, smoking status, and pertinent intraoperative information, including American Society of Anesthesia (ASA) Physical Status Classification, anesthesia, and operative time (anesthesia sign in to sign out). Aortic neck diameter, circumference and length, iliac diameter, and length of the landing zone were recorded, and compliance with graft IFU guidelines was documented. 14, 15 Need for additional aortic cuffs or limb extenders was noted. Contralateral limbs, routinely used with Excluder (graft B; W. L Gore and Associates, Flagstaff, Ariz) and aortic cuff used in 85% of Powerlink (graft A; Endologix, Irvine, Calif) were considered standard elements for each of the grafts, respectively. Only supplementary use beyond this was designated as an additional component. Use of PEVAR was monitored. Most surgeons favored a PEVAR-first approach, but that decision was discretionary. PEVAR guidelines 13 were not strictly observed.
Intraoperative and postoperative complications, hospital length of stay (LOS), and 30-day readmission were documented. Follow-up from the surgeon's office included evaluation for endoleak, reintervention, and mortality. Effect of IFU and additional graft components on outcomes was analyzed per vendor.
Financial data were obtained through the hospital's Decision Support team using the Allscripts (Chicago, Ill) Enterprise Performance System (EPSi). This system combines general ledger and patient data to provide complete financial information for each patient admission, including reimbursement, charge, total cost with breakdown into direct and indirect costs and cost detail by department. Cost and reimbursement data were analyzed. Contribution margin (CM), a financial metric used by hospitals to assess fiscal productivity, was recorded. CM is calculated by subtracting direct costs from reimbursement, thus removing the effect of indirect costs from analysis. Total hospital and operating room (OR) costs were recorded, as were itemized costs for OR use (endografts, aortic cuffs, limb extenders, closure devices, other OR supplies) and anesthesia (including the professional component). Surgeon's fees and costs of preoperative evaluation were not included.
The c 2 , Student t-test for independent samples, analysis of variance, and Kaplan-Meier survival were performed. Significance was reported at P # .05. Statistical analysis was completed using SPSS 22 software (SPSS Inc, Armonk, NY).
RESULTS
The sample comprised 67 elective EVARs (72.8%) of all EVAR. Excluded were 25 cases: 11 ruptured AAAs, 8 urgent admissions, and 6 EVARs completed during a concomitant hospitalization for an alternate diagnosis. Demographics and comorbidities reported in Table I were representative of the AAA population at large. Only 7% were graded ASA class IV risk. General anesthesia, used in 55 (88%), was related to surgeon The cost of the baseline graft with and without aortic cuff or limb extensions by vendor reveals that additional components raised costs significantly above baseline for each graft, respectively, but that costs of baseline grafts were comparable for each vendor, as were grafts with additional components. Graft costs were increased for both vendors when EVAR was completed outside of the IFU guidelines, particularly limb IFU. b Data are presented as mean 6 standard deviation. neck length (27.8 6 10.1 mm vs 9.8 6 3.9 mm; P < .001).
The mean iliac artery diameter was significantly larger in cases that did not meet the IFU (39.4 6 16.4 mm vs 14.5 6 3.7 mm; P ¼ .03). Neck length was shorter in those requiring an additional cuff (16 6 8 mm vs 26 6 12 mm; P ¼ .05), and angulation was more severe (50 6 45 vs 23 6 20 ; P ¼ .12). The need for a limb extension was significantly related to an inadequate seal zone (100% vs 21%; P < .001) and to a trend when arteries were aneurysmal (23 6 15 mm vs 14 6 5 mm; P ¼ .06).
Inadequate seal documented in 10 (14.9%) on initial completion angiogram was noted only with graft A or B: 16.1% (A: 7.1% vs B: 23.5%; P ¼ .08). The index graft failed to seal the aortic neck in eight (12.9%; graft A: 7.1% vs B: 17.6%; P ¼ .22). Inadequate seal in the iliac arteries occurred in three (4.8%), necessitating additional components (graft A: 3.6% vs B: 5.9%; P ¼ .67). One patient with graft A had inadequate seal at both proximal and distal landing zones and required an aortic cuff and distal extension. One type III endoleak (1.5%) was noted with graft B (2.9% vs 0%; P ¼ .36). All type I or III endoleaks were repaired intraoperatively with complete resolution: type I with balloon angioplasty (n ¼ 2), proximal cuff (n ¼ 7), or distal extension graft (n ¼ 2) and type III with a limb extender. Type II endoleak was present in 10 (14.9%) of all grafts at the conclusion of surgery and was significantly higher for graft B than A (23.5% vs 0%; P ¼ .006). Type II endoleak occurred with grafts from the other two manufacturers, but small numbers did not permit analysis.
Placement of additional graft components was necessary in 28 patients (37%), was similar for graft A (32.1%) vs graft B (47.1%; P ¼ .23) and included aortic cuffs in 14.3% and 14.7% (P ¼ .96) of the grafts, respectively, and limb extenders in 21.4% and 35.3% (P ¼ .23). Concomitant placement of aortic cuff/limb extension (reflected in the above totals) was also similar (A: 7.1% vs B: 2.9%: P ¼ .44). One individual with graft A required placement of a second graft because of incorrect deployment of the initial graft.
Aortic neck IFU was significantly related to placement of additional cuffs for graft B (4% vs 67%; P < .001) but not for graft A (13% vs 25%; P ¼ .51). Limb IFU was significantly related to a need for limb extension in graft A (5% vs 83%; P < .001) and graft B (30% vs 100%; P ¼ .016). Placement of additional components significantly increased the OR time (216 6 79 minutes vs 169 6 67 minutes; P ¼ .016). Omnipaque (Nycomed Amersham, Princeton, NJ)/Visipaque (GE Healthcare Inc, Princeton, NJ) used for intraarterial imaging (median, 70 mL; mean, 77 mL) did not differ by graft manufacturer (P ¼ .50) but was significantly higher in those who required extensions (96 mL vs 64 mL; P ¼ .004). Extension placement and contrast use >70 mL (median) were associated with bumps in postoperative creatinine ([0.06 mg/dL vs Y0.13 mg/dL; P ¼ .016) and ([ 0.06 mg/dL vs Y0.14 mg/dL; P ¼ .01) respectively. No postoperative renal failure requiring dialysis occurred.
Intraoperative complications were similar by graft (P ¼ .84) and need for additional components (P ¼ .31). Major postoperative complications included myocardial infarction (MI) in 3%, congestive heart failure (CHF) in 1.5%, and respiratory failure in 1.5%, and occurred comparably across manufactures (MI, P ¼ .98; CHF, P ¼ .81; respiratory failure, P ¼ .41) and was not related to placement of intraoperative cuffs or extensions (MI, P ¼ .71; CHF, P ¼ .44; respiratory failure, P ¼ .36).
Baseline graft costs were similar (A: $15,363 vs B: $14,780; P ¼ .39). Supplemental components increased the graft cost significantly above its respective baseline. However, increases were comparable, so the cost of grafts with additional components were similar for both vendors Table IV ). Graft costs were also higher for EVAR performed outside of IFU, particularly limb EVAR (Table III) . PEVAR was attempted in 61 of elective EVARs (91%): bilateral approach (BilatPEVAR) in 49 (73%), unilateral (UnilatPEVAR) in 7 (10%), and was unsuccessful (failed PEVAR) in 5 (8%). Calcific vessels, unusual anatomy, and groin scarring were common factors that impeded success. Typically, four (range, 1-9) closure devices were, used averaging $1000 per case or 3.5% of the total hospital expenditure. Operative time did not vary by number of closure devices used (range, 1-9; P ¼ .211) but was lowest among BilatPEVAR (2 hours 44 minutes) vs Unilat-PEVAR (3 hours 48 minutes) and failed PEVAR (5 hours 10 minutes; P < .001). Successful BilatPEVAR was possible in 17 (68%) who required additional graft components and in 32 (76%) who did not (P ¼ .46). Patients who had BilatPEVAR or UnilatPEVAR were more likely to be discharged on the first postoperative day than those in whom PEVAR was unsuccessful (86% vs 57% vs 20%; P ¼ .002).
Financial metrics showed that the cost for using the OR, total hospital costs, and CM were most optimal among BilatPEVAR; costs of failed PEVAR were similar to non-PEVAR (Table V) . Intraoperative complication (P ¼ .25), operative time (P ¼ .31), hospital LOS (P ¼ .49), 30-day readmission (P ¼ .25), and reintervention rates (P ¼ .34) for failed PEVAR were similar to non-PEVAR.
Thirty-day EVAR-related readmission was four (6.0%). All occurred in graft B (11.8% vs 0%; P ¼ .07) with supplemental components (16.7% vs 0%; P ¼ .008). Reasons for readmission were exploratory laparotomy for inflammatory bowel changes without ischemia, exacerbation of CHF and possible graft leak, which was ruled out, symptomatic blood loss anemia requiring transfusion, and new-onset of atrial fibrillation, with CHF and acute nephropathy thought possibly related to contrast load; however, the patient had received only 50 mL of Omnipaque.
Endoleak was identified in 28.3% during follow-up. Type I occurred in 9.4% (5.7% Ia and 3.7% Ib) and included 3.7% concomitant type II endoleak. Development was similar for both grafts (A: 9.5% vs B: 11.1%; P ¼ .86) and was significantly related to placement of additional components during the index procedure (21% vs 3.5%; P ¼ .05) All reinterventions occurred between 1 and 25 months. A type II-only endoleak was noted in 17%, including 11% that were present at case completion and persisted into follow-up (mean, 22 months) and 6% that developed during follow-up (mean, 15 months; range, 7-24 months) and are currently being observed. Although type II endoleak was more prevalent with graft B (33.3%) vs graft A (4.8%; P ¼ .016), 80% of all type II leaks were observed. Most that underwent reintervention had concomitant type I endoleak (B: 7.4% vs A: 0%; P ¼ .20). One type III endoleak developed at 14 months and was also observed.
Reintervention during follow-up was required in six (11.3%); five (9.4%) for treatment of type I endoleak and one (1.9%) for increasing sac size without clear evidence of a leak at reintervention. Two (3.7%) required secondary reintervention: one for type Ia endoleak with increasing sac size and the second for persistent sac growth from an additional type II endoleak.
Aortic neck IFU, failure of the index graft to seal the aortic neck, and need for additional aortic cuff were all significantly related to need for reintervention for type Ia endoleak for graft B but had little effect on graft A. In contrast, limb IFU was significantly related to the need for additional limb extension for graft A. Moreover, 
DISCUSSION
Repair of AAA by EVAR has become standard practice during the past decade. Undoubtedly, its benefits are numerous, but come with a high price tag. Long-term clinical outcomes are favorable, but early reintervention rates range between 10% and 15%. 3, 5, 12, 16, 17 Anatomic suitability favorably influences technical success and outcome 4 ; yet, EVAR has been shown to be effective in a hostile anatomy. 3, 6, 7 Subsequently, surgeons are increasingly performing EVAR outside of IFU guidelines. A number of endografts with varying configurations are routinely used. The base graft is usually sufficient to exclude the aneurysm sac. However, we found that additional aortic cuffs, limb extenders, or stents were necessary in one-third to nearly one-half of the two most frequently used grafts to achieve adequate seal at the proximal or distal fixation zones. Use of additional components was significantly higher for both grafts when IFU criteria were not met. Excellent results were achieved for both grafts when EVAR was performed within the IFU, and additional components were unnecessary; however, rates of reintervention increased when IFU criteria were not met or when additional components were required. Interestingly, each graft performed differently in complex anatomy, with graft A potentially more favorable for aortic neck anatomy that does not meet IFU and graft B for treating complex limb anatomy. Reintervention for type Ia endoleak was significantly elevated for graft B placed in aortic anatomy that did not meet the IFU or required additional aortic cuff placement, or both; yet, these factors had little effect on the reintervention rates for graft A. In contrast, limb IFU and extension had a limited effect on reintervention for type Ib endoleak for graft B, whereas for graft A, limb IFU was significantly related to the need for limb extension, which was associated with an increased trend for reintervention.
The 24-month reintervention-free rates were excellent for both grafts, yet different patterns of reoperation were observed. Type Ia or Ib endoleak occurred early for graft A, requiring repair <2 months, but remained stable thereafter. In contrast, reintervention was not required until 23 months for graft B, remained unchanged for the balance of follow-up for type Ib, but declined to 80% at 25 months for type Ia endoleak; notably lower than the 94.6% reported in the Italian Excluder Registry at 3 years. 4 Knowledge of the subtle variability in graft performance may help surgeons to tailor graft selection according to anatomic suitability and patient longevity, which could potentially improve outcome for all EVAR, but particularly those cases that fall outside of the IFU. Current studies usually document only those endoleaks that remain at case completion. Technical success achieved through adjunctive procedures is not routinely differentiated. We found that secondary development of endoleaks and the need for reintervention was higher when additional components were required to achieve an adequate seal. This group may warrant closer surveillance. Type II endoleak was present in <20%, two-thirds of which were evident at case completion and one-third that developed #24 months postoperatively. Type II endoleak was statistically more prevalent in graft B, but this may be of little clinical consequence because 80% of all type II endoleaks required monitoring only and most that underwent reintervention had concomitant type I endoleak. Operative time and contrast load were significantly increased when additional components were required, but generally, this was associated with subclinical rises in postoperative creatinine only. One patient required hospital readmission <30 days for contrast nephropathy but had received a lower dose of contrast. All 30-day EVAR-related hospital readmissions occurred in patients who had required additional components. Indications for readmission were not directly related to the graft itself or to additional components, but longer operative times and increased contrast load may have been contributory.
Graft costs, with and without additional components, were similar for both vendors. Additions increased graft cost significantly over its baseline, raised total hospital costs significantly, reduced the CM by $2000 absolute dollars, shifted profit to loss, and may present an opportunity for renegotiation with vendors. Fortunately, the Centers for Medicare and Medicaid increased reimbursement for EVAR in October 2015 concurrent with implementation of the International Classification of Disease-10th Revision. Compensation for noncomplex EVAR increased 15% and complex cases 24%, 18 which should improve the CM for hospitals. Many medical centers currently evaluate surgeons on quality and fiscal measures. We found that EVAR performed outside of the IFU guidelines or use of additional graft components, or both, negatively affected outcome and cost. This could potentially result in poorer grades for physicians by administrators who are unaware of the dynamics at play. Surgeons must elucidate the complex relationship between case mix and performance to hospital executives. EVAR performed outside of the IFU will be associated with increased costs and higher reintervention rates, but the alternative is open repair with associated intensive care unit admission, longer hospital LOS, and lower patient appeal.
Maintaining a competitive advantage in the current health care market is closely linked to providing cutting edge technology, which is inherently costly and strains hospital operating budgets. Administrators tasked with the daunting endeavor of balancing the two rigorously search for opportunities to maximize profit or at least minimize loss. Endografts are big-ticket items that may be easily targeted for cost reduction by limiting graft choice. Use of less expensive grafts has been suggested for situations in which grafts can be used interchangeably.
11 However, reintervention rates should be considered, because the additional expenditure for reoperation may prove to be more costly in the long-run.
Meticulous attention to graft selection should provide an excellent opportunity for cost containment and outcome improvement. Closure devices are also costly items that may likewise be scrutinized. These devices were associated with shorter hospital LOS, anesthetic, and OR times, which offsets device cost and supports their use even when a larger number of devices are required. Additional components did not preclude successful PEVAR. PEVAR may actually prove beneficial in offsetting the lengthened operative time associated with these cases.
However, forcing challenging anatomy to PEVAR may result in poorer success rates and increased expenditure. We noted that all failed PEVARs were performed outside of PEVAR guidelines. 13 However, because of the study's retrospective design, we were unable to ascertain the incidence of PEVAR that did not meet guidelines but were performed successfully (BilatPEVAR). In addition, failed PEVAR was more costly than BilatPEVAR, yet its cost and outcomes remained similar to primary closure. Therefore, unless serious concerns for failure based on anatomy and femoral artery atherosclerosis are evident, attempting PEVAR may still be reasonable. This study has some limitations. It was a small and nonrandomized study, so results may not be generalizable. Surgeons chose which graft to use, and factors that affected that decision are not easily discernible on retrospective review. However, we believe this study provides a preliminary appraisal of the clinical and financial outcomes when EVAR is performed outside of the IFU for complex anatomy or additional graft components, or both, are required and believe this may provide a foundation for future trials.
CONCLUSIONS
Additional graft components were required in one-third to one-half of two commonly used grafts and were strongly associated with the IFU, increased the need for reintervention, and raised graft costs by one-third. Each graft performed differently in complex aortic neck or limb anatomy. Despite equivalent reintervention-free rates, different patterns of reoperation were noted. Fastidious attention to these details during graft selection can likely improve outcome and contain costs. Moreover, attempting PEVAR may be practical barring substantial concern for failure. Successful PEVAR was associated with lower costs and earlier discharge, and costs and outcomes of failed PEVAR were not inferior to cutdown. 
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